Print this page    •   Back to Web version of article

Antiretroviral Therapy
(Part XXIV)
Update from the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication

By Steven G. Deeks, M.D.

November 7, 1997

AIDS INFORMATION NEWSLETTER
AIDS Information Center VA Medical Center, San Francisco

Over the past year, viral resistance to antiretroviral agents has emerged as the dominant issue facing clinicians and patients. It is therefore not surprising that the annual resistance meeting has evolved to be one of the most important and eagerly awaited scientific conferences of the year. This year, to maintain an informal "workshop" environment, attendance was limited to approximately 200 scientists. Many representatives from academia, industry, advocacy groups, and the media were unable to attend.

This report will highlight some of the key presentations, focusing on presentations that have direct clinical implications or provide novel insights into drug resistance. As an introduction, this report begins with a brief review of resistance assays and mutation patterns associated with each of the 11 currently available agents.

Contents:

HIV-1 Resistance: A Primer

Protease Inhibitor Resistance and Drug Failure Viral Load and Genotypic Resistance Assays Protease Inhibitors and Long-Term Viral Suppression Mechanisms of Antiretroviral Resistance References




This article was provided by U.S. National Institute of Allergy and Infectious Diseases. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art6618.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.